Close Menu

electrospray ionization mass spectrometry

A Mayo Clinic research group that previously evaluated Abbott's PCR-electrospray ionization mass spectrometry platform to broadly identify fungal infections has now published research demonstrating the system's ability to identify Mycobacterium species and M.

Researchers from the Mayo Clinic have demonstrated that Abbott's Plex-ID broad fungal assay is as good or in some cases better than culture-based methods for identifying fungal infections to the species level directly from respiratory specimens without prior knowledge of the offending orga

Scientists from Abbott and collaborating academic institutions have recently published a pair of studies demonstrating the ability of Abbott's Plex-ID platform to detect and identify in human samples a wide array of clinically relevant infectious organisms not picked up using mor

NEWPORT BEACH, Calif. – Scientists at Abbott subsidiary Ibis Biosciences have developed an assay to detect and genotype Borrelia burgdorferi, the bacterium responsible for causing Lyme disease in humans, using Abbott's Plex-ID microbial identification system.

NEW YORK (GenomeWeb News) – PerkinElmer is suing Agilent for infringement of two patents covering mass spectrometry technology.

NEW YORK (GenomeWeb News) – Waters and Protea Biosciences today announced a co-marketing deal to offer customers Waters' SYNAPT G2 & G2-S HDMS systems with Protea's LAESI DP-1000.

Abbott said today that it has entered into an agreement with the University of North Texas Health Science Center to evaluate the company's Plex-ID instrument for use in analyzing human remains to support missing persons and human trafficking investigations.

The company will use GSG Mess-und Analysnegerate for marketing and distribution in Germany, Austria, and Switzerland.

Abbott's Plex-ID system, which combines PCR and mass spec analysis, will help authorities at state public health labs identify and characterize microorganisms in surveillance activities for infectious diseases, food safety analysis, and biodefense readiness.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.